discovered that CD8+ T cells activated by cancer immunotherapy could release IFNγ to reduce SLC3A2 and SLC7A11 expression, leading to cell lipid peroxidation and ferroptotic cell death in cancer cells (26). This evidence concerns the gene CD8A and cancer.